The Whistleblower Institute announces that Mylan reached a $465 million settlement in a whistleblower lawsuit.
San Diego, CA -- (SBWIRE) -- 09/25/2017 -- The Whistleblower Institute announces that Mylan reached a $465 million settlement in a whistleblower lawsuit filed by a competing pharmaceutical manufacturer, for knowingly misclassifying EpiPen as a generic drug to avoid paying rebates owed to Medicaid.
Those who have a similar case or experienced a similar situation or any other wrongdoing within a corporation have certain options and should contact the Whistleblower Institute at firstname.lastname@example.org or call: 619-452–1218. There are no costs or obligations to you.
A settlement has been reached to resolve False Claims Act allegations against Mylan Inc and Mylan Specialty L.P.
The allegations arose from a lawsuit that claimed Mylan Inc and Mylan Specialty L.P. knowingly misclassified EpiPen, a branded epinephrine auto-injector drug, as a generic drug to avoid paying rebates owed to Medicaid.
According to the government, Mylan allegedly improperly avoided paying state Medicaid programs the higher rebates for branded drugs by misclassifying EpiPen as a generic drug, even though EpiPen had no FDA-approved therapeutic equivalents and even though Mylan marketed and priced EpiPen as a brand name drug. Mylan raised the price of EpiPen by approximately 400% between 2010 and 2016.
Reportedly, as part of this settlement, Mylan has also entered into a corporate integrity agreement with the Department of Health and Human Services Office of Inspector General (HHS-OIG) that requires, among other things, an independent review organization to annually review multiple aspects of Mylan's practices relating to the Medicaid drug rebate program.
Sanofi, a competing pharmaceutical manufacturer brought this matter forward. In 2016, Sanofi filed a complaint against Mylan under the qui tam provisions of the False Claims Act, which permits private parties to sue on behalf of the government and to receive a share of any recovery.
Sanofi's share of the settlement will be $38.7 million.
"Mylan misclassified its brand name drug, EpiPen, to profit at the expense of the Medicaid program," said Acting United States Attorney William D. Weinreb. "Taxpayers rightly expect companies like Mylan that receive payments from taxpayer-funded programs to scrupulously follow the rules. We will continue to root out fraud and abuse to protect the integrity of Medicaid and ensure a level playing field for pharmaceutical companies. We commend Sanofi for bringing this matter to our attention."
Based in Canonsburg, Pennsylvania, Mylan is an American global generic and specialty pharmaceuticals company.
The Whistleblower Institute is an information portal for current or former employees and other people having insight information about wrongdoing and other illegal activities by individuals either individually or within corporations, through company culture and or within international affairs. Whistleblowers should keep in mind that under the Dodd-Frank Act any person who provides the Securities and Exchange Commission ("SEC") with original information that leads to a successful enforcement action with over $1 million recovered must be awarded between 10%-30% of the total amount recovered. In order to determine the total amount of the reward there are numerous factors that need to be considered. Whistleblower actions are complex and our goal is to guide any whistleblower every step of the way. The Whistleblower Institute is dedicated to partnering with any individual who have information about fraud and we work with many of the best law firms worldwide.
Those who have a similar case or experienced a similar situation or any other wrongdoing within a corporation have certain options and should contact the Whistleblower Institute.
2534 State Street - Suite 406
San Diego, CA 92101, USA
Phone: +1 (619) 452–1218
Facsimile: +1 (619) 785 – 3185
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Whistleblower Institute